Eli Lilly’s Bold Pricing Move Sparks Investor Debate
Published on 12/02/2025 at 05:01 | Redaktion boerse-global.de
Having recently surpassed the historic $1 trillion market capitalization milestone, pharmaceutical titan Eli Lilly now faces pressure on its share price. The catalyst is a bold strategic shift: implementing significant price reductions for its blockbuster weight-loss drug, Zepbound. This aggressive move has left market participants questioning whether the company is sacrificing profitability for market dominance or strategically igniting a new phase of expansion.
In a direct challenge to Danish rival Novo Nordisk, Eli Lilly has launched substantial price cuts for Zepbound on its LillyDirect platform. The monthly cost for the 2.5-mg single-dose pen has been reduced from $349 to $299. An even steeper discount applies to the 5-mg dose, which now costs $399, down Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
